nobabelle 0,075 mg + 0,03 mg tabletki
egis pharmaceuticals plc - gestodenum + ethinylestradiolum - tabletki - 0,075 mg + 0,03 mg
nobabelle daily 0,075 mg + 0,02 mg tabletki
egis pharmaceuticals plc - ethinylestradiolum + gestodenum - tabletki - 0,075 mg + 0,02 mg
nobabelle daily 0,075 mg + 0,03 mg tabletki
egis pharmaceuticals plc - gestodenum + ethinylestradiolum - tabletki - 0,075 mg + 0,03 mg
atywia daily 0,03 mg + 2 mg tabletki powlekane
exeltis poland sp. z o.o. - ethinylestradiolum + dienogestum - tabletki powlekane - 0,03 mg + 2 mg
astha 0,03 mg + 2 mg tabletki powlekane
aristo pharma sp. z o.o. - ethinylestradiolum + dienogestum - tabletki powlekane - 0,03 mg + 2 mg
alunbrig
takeda pharma a/s - brigatinib - rak, niedrobnokomórkowe płuca - Środki przeciwnowotworowe - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - Środki przeciwnowotworowe - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
clormetin 0,03 mg + 2 mg tabletki powlekane
exeltis poland sp. z o.o. - ethinylestradiolum + chlormadinoni acetas - tabletki powlekane - 0,03 mg + 2 mg
belara conti 2 mg + 0,03 mg tabletki powlekane
gedeon richter polska sp. z o.o. - chlormadinoni acetas + ethinylestradiolum - tabletki powlekane - 2 mg + 0,03 mg